Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

It isn't just girls experiencing serious injuries after receiving the Gardasil vaccine

Baum Hedlund Aristei & Goldman

News provided by

Baum Hedlund Aristei & Goldman

Sep 16, 2020, 19:56 ET

Share this article

Share toX

Share this article

Share toX

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed a Gardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Continue Reading
Zach Otto with his pet, Jekyll
Zach Otto with his pet, Jekyll
Zach Otto before his first Gardasil shot
Zach Otto before his first Gardasil shot

Attorneys Bijan Esfandiari, Nicole K. H. Maldonado, Michael L. Baum, and co-counsel Robert F. Kennedy, Jr. filed the latest Gardasil lawsuit in Superior Court for the State of California, County of Orange against Merck & Co. Inc. and subsidiary Merck Sharp & Dohm Corp., both of New Jersey. The complaint (Case No. 30-2020-01160496-CU-PL-CJC), which seeks punitive damages, accuses Merck of negligence and failure to warn of dangerous side effects related to its Gardasil HPV vaccine, among other causes of action.

Plaintiff Zachariah (Zach) Otto received his first Gardasil shot in Orange County, California when he was 16 years of age. Mr. Otto, now 24 and living in Colorado, alleges multiple Gardasil injections caused him to develop life-altering injuries that have left him unable to work or physically attend college.

"Most people think Gardasil is for girls, but since 2009, Merck has made billions in profit by marketing the HPV vaccine to the parents of boys and to young men," says attorney Nicole K.H. Maldonado. "Through its advertising, Merck sold parents on the idea that Gardasil is a safe and effective tool to stop the spread of HPV and prevent cervical cancer. But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."

"Merck fast-tracked Gardasil by presenting misleading data to the FDA and fabricating a health crisis," says Mr. Otto's co-counsel Robert F. Kennedy Jr. "They claimed they were 'filling an unmet medical' need but in reality, the only thing Merck was interested in filling was the $6 billion financial hole created by the Vioxx scandal."

Plaintiff Zach Otto Developed Several Vaccine Injuries After Receiving Gardasil Shots

Zach Otto was a 16-year-old minor when he received his first shot of Gardasil in 2012. Before agreeing to allow Zach to receive the Gardasil vaccine, his mother, Jennifer Otto, relied upon Merck's ubiquitous representations concerning the vaccine's safety and efficacy. She had viewed various online, print, and television marketing materials stating that Gardasil is very safe, that Gardasil prevents cancer, and that "good mothers" must vaccinate their children with the Gardasil vaccine. 

In 2014, Zach received his second Gardasil injection. He shortly thereafter experienced body pains, headaches, cold-like symptoms, unexplained rashes, joint pains, ear pain, and enhanced lymph nodes in his neck. Over the next few months, Zach was in and out of doctors' offices to treat his symptoms.

In 2015, Zach received his third Gardasil injection. Two days later, his knees gave out while he was at work. Unable to move, he called his mother to take him home.

Mr. Otto's health continued to decline in the months that followed. He experienced numerous serious and disabling complications, including weakness, chronic pain in joints, abnormal gait, burning sensation on various parts of his body, hives, extreme weight loss, chronic fatigue, rashes, gastrointestinal issues, severe headaches, inability to sleep, dizziness upon standing, memory and cognitive issues, dysautonomia, and the inability to walk any significant distance without a cane, among many other issues.

In 2016, Mr. Otto tested positive for postural orthostatic tachycardia syndrome (POTS), an autoimmune disorder in which people often experience fainting, migraine headaches, anxiety, and a host of other life-changing health issues.

As a result of his injuries, Mr. Otto is unable to engage in the normal activities that a teenager and young adult would enjoy; he had to drop out of college for a time and can no longer work. He is now legally disabled and must live with his mother who acts as his primary caregiver.

Mr. Otto is visited by nurses at his home that administer his intravenous immunoglobulin (IVIg) therapy to help combat his autoimmune injuries. IVIg therapy is expensive and time-consuming with the recipient hooked up to an IV for hours on end.

Even with treatment, Zach continues to experience many of the Gardasil-induced symptoms outlined above and is forced to be homebound, bedbound, and remains generally inactive. His serious and disabling physical injuries, pain, and mobility limitations have also had a devastating impact on his emotional wellbeing. 

According to the complaint, if Mr. Otto knew of the risks associated with the vaccine, he never would have consented to receive it. Likewise, if his mother had been informed about the known safety risks associated with the Gardasil vaccine, she never would have allowed her son to receive his first Gardasil injection.

In filing today's complaint, Zach Otto seeks to hold Merck accountable for causing his life-changing physical and emotional injuries. The complaint accuses Merck of knowingly and recklessly placing Gardasil's profits ahead of patient safety. He is requesting that exemplary (punitive) damages be assessed to deter Merck and other would-be defendants from engaging in similar alleged reprehensible conduct.

Gardasil Lawsuit Allegations

Among other allegations, the complaint filed today accuses Merck of the following (these are allegations only, there has been no determination of liability in this matter):

  • Merck misled regulators, legislators, and the medical community about the safety and efficacy of the Gardasil HPV vaccine. The vaccine manufacturer knowingly concealed the risks associated with Gardasil's ingredients, which include a potent neurotoxin and potentially hazardous DNA particles.
  • In seeking fast-track approval for Gardasil, Merck presented misleading data to the FDA suggesting that HPV infections and some abnormal cervical tissue inexorably result in cancer. Gardasil's approval was based on Merck's theory that HPV alone causes cervical cancer, and that the Gardasil vaccine could eliminate cervical cancer and other HPV-associated cancers. None of these contentions are true; Merck has never proven that Gardasil prevents cervical cancer or any type of cancer.
  • In the Gardasil clinical trials, Merck did not use a true placebo. Instead, Merck "spiked" the placebo with AAHS and the vaccine's other additives, which resulted in approximately equal numbers of subjects in the vaccine group and the placebo group suffering adverse reactions. According to the complaint, this gave the false impression that the Gardasil HPV vaccine was "as safe as a placebo" when, in fact, significant numbers of subjects in both treatment groups suffered many serious medical conditions, including symptoms of autoimmune disease.
  • Contrary to Merck's assertions that Gardasil is a safe and effective tool for preventing cancer, studies have shown that systemic administration of Gardasil leads to increased rates of cervical cancer and other serious health issues, including the severe side effects Mr. Otto now suffers.
  • Merck knew or had reason to know that its vaccine was defective and ineffective, but instead of warning the medical community and the public, the company wrongfully concealed information and further made false statements concerning the safety and efficacy of Gardasil.
  • Gardasil has more reported injuries than any other vaccine on the market. The Vaccine Injury Compensation Program has paid out millions of dollars in damages for Gardasil-induced injuries and deaths. Despite these injuries and deaths, Gardasil is the most expensive vaccine currently on the market.

About Zach Otto

"My life is a constant battle between attempting to improve my life and being held back by my own body's limitations," says Mr. Otto. "Gardasil has turned my body into a prison, an anchor that won't afford me the ability to live an independent life and one that significantly restricts my ability to grow as a person. Life with vaccine injuries has been a battle, not just to survive, but to live. It's the myriad of doctor appointments and tests, the IVIg I receive every three weeks just to get some level of relief from the chronic pain and weakness that I suffer every day."

About Baum Hedlund Aristei & Goldman

Baum Hedlund Aristei & Goldman is one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine. In August, the firm filed a similar Gardasil lawsuit on behalf of 19-year-old Julia Balasco, who alleges she sustained severe injuries after receiving her first Gardasil shot at the age of 13.

Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Statement from Baum Hedlund Aristei & Goldman on the Gardasil Litigation  

It is important to note that, while there is currently a great deal of controversy surrounding vaccines, the attorneys at Baum Hedlund Aristei & Goldman wish to stress that we and our clients are not against vaccines. Vaccines have the potential to eradicate disease and save millions of lives.

However, our firm is against intentional efforts to mislead consumers about the safety and effectiveness of a drug or vaccine. We have always fought—and will continue to fight—for the rights of consumers to be fully and honestly informed about risks associated with any drug, vaccine, chemical, or medical device. We will work tirelessly to ensure those rights are defended and victims of injustice are compensated for their injuries.

SOURCE Baum Hedlund Aristei & Goldman

Related Links

https://www.baumhedlundlaw.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.